Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes
Go back to Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes| (NASDAQ: ZEAL) | Delayed: 17.59 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.59 | 52 Week High | $ | |||
| Open | $1.35 | 52 Week Low | $ | |||
| Day High | $17.59 | P/E | N/A | |||
| Day Low | $17.59 | EPS | $ | |||
| Volume | 15,962 | |||||



